CERo Therapeutics Holdings (CERO) Price & Analysis

Compare

450 Followers

CERO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.71 - $894.94

Previous Close$3.66

Volume998.67K

Average Volume (3M)51.79K

Market Cap

$9.34M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta-0.79

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-38.99

Shares Outstanding1,205,402

10 Day Avg. Volume29,027

30 Day Avg. Volume51,789

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$30.00

Price Target Upside298.94% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe first AML patient has been dosed with CER-1236 cell therapy, marking a major milestone for the company.

Innovative TherapeuticsCER-1236 cells are a novel approach to T cell-based therapeutics, incorporating unique elements like the phagocytic receptor TIM-4.

Bears Say

Corporate ActionsThe company announced a 1:20 reverse stock split.

CERo Therapeutics Holdings News

Cero Therapeutics files to sell 9.62M shares of common stock for holders

06:05 EDT Cero Therapeutics (CERO) files to sell 9.62M shares of common stock for holders Published first on...

20d ago

CERO

CERo Therapeutics Delays 10-Q Filing Amid Valuation Issues

CERo Therapeutics Holdings ( ($CERO) ) has released a notification of late filing. CERo Therapeutics Holdings has announced...

15d ago

CERO

Cero Therapeutics doses second patient in Phase 1 CER-1236 trial

CERo Therapeutics (CERO) announces it has dosed the second patient in the first cohort of its Phase 1...

1M ago

CERO

Cero Therapeutics files to sell 12.5M shares of common stock for holders

The company will not receive any proceeds from the issuance or sale of the common stock. Published first...

1M ago

CERO

CERo Therapeutics Completes Series D Stock Sale

CERo Therapeutics Holdings ( ($CERO) ) has shared an announcement. CERo Therapeutics Holdings, Inc. has completed multiple closings...

1M ago

CERO

CERo Therapeutics Enters New Stock Purchase Agreement

CERo Therapeutics Holdings ( ($CERO) ) just unveiled an announcement. On July 11, 2025, CERo Therapeutics Holdings entered...

2M ago

CERO

CERo Therapeutics Regains Nasdaq Compliance by July 2025

CERo Therapeutics Holdings ( ($CERO) ) just unveiled an announcement. On June 11, 2025, CERo Therapeutics Holdings received...

2M ago

CERO

CERo Therapeutics Completes Additional Series D Funding

The latest announcement is out from CERo Therapeutics Holdings ( ($CERO) ). CERo Therapeutics Holdings recently engaged in...

2M ago

CERO

Cero Therapeutics upgraded to Buy from Hold at D. Boral Capital

D. Boral Capital upgraded Cero Therapeutics (CERO) to Buy from Hold with a $30 price target With the...

2M ago

CERO

Cero Therapeutics’ first patient completes dose-limiting toxicity observation

The company states: “CERo Therapeutics (CERO) announces the completion of the initial evaluation of the first patient in...

2M ago

CERO

CERo Therapeutics Holdings Inc trading resumes

09:56 EDT CERo Therapeutics (CERO) Holdings Inc trading resumes Published first on TheFly – the ultimate source for...

2M ago

CERO

CERo Therapeutics Holdings Inc trading halted, volatility trading pause

09:46 EDT CERo Therapeutics (CERO) Holdings Inc trading halted, volatility trading pause Published first on TheFly – the...

2M ago

CERO

CERo Therapeutics Gains FDA Orphan Drug Designation

CERo Therapeutics Holdings ( ($CERO) ) has shared an update. On June 17, 2025, CERo Therapeutics Holdings announced...

2M ago

CERO

Cero Therapeutics announces FDA ODD granted to CER-1236

CERo Therapeutics (CERO) announces that the U.S. Food and Drug Administration, FDA, has granted CERo’s Orphan Drug Designation,...

2M ago

CERO

CERO FAQ

What was CERo Therapeutics Holdings’s price range in the past 12 months?

CERo Therapeutics Holdings lowest stock price was $6.71 and its highest was $894.94 in the past 12 months.

What is CERo Therapeutics Holdings’s market cap?

CERo Therapeutics Holdings’s market cap is $9.34M.

When is CERo Therapeutics Holdings’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were CERo Therapeutics Holdings’s earnings last quarter?

Currently, no data Available

Is CERo Therapeutics Holdings overvalued?

According to Wall Street analysts CERo Therapeutics Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CERo Therapeutics Holdings pay dividends?

CERo Therapeutics Holdings does not currently pay dividends.

What is CERo Therapeutics Holdings’s EPS estimate?

CERo Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CERo Therapeutics Holdings have?

CERo Therapeutics Holdings has 1,205,402 shares outstanding.

What happened to CERo Therapeutics Holdings’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of CERo Therapeutics Holdings?

Among the largest hedge funds holding CERo Therapeutics Holdings’s share is Saba Capital Management. It holds CERo Therapeutics Holdings’s shares valued at 0.

CERo Therapeutics Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-34.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CERo Therapeutics Holdings

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

CERo Therapeutics Holdings (CERO) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

CERO Stock 12 Month Forecast

Average Price Target

$30.00

▲(298.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","550":"$550","142.75":"$142.8","278.5":"$278.5","414.25":"$414.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,142.75,278.5,414.25,550],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.93,10.55076923076923,12.17153846153846,13.792307692307691,15.413076923076922,17.033846153846156,18.654615384615383,20.275384615384617,21.896153846153844,23.516923076923078,25.13769230769231,26.75846153846154,28.37923076923077,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.93,10.55076923076923,12.17153846153846,13.792307692307691,15.413076923076922,17.033846153846156,18.654615384615383,20.275384615384617,21.896153846153844,23.516923076923078,25.13769230769231,26.75846153846154,28.37923076923077,{"y":30,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.93,10.55076923076923,12.17153846153846,13.792307692307691,15.413076923076922,17.033846153846156,18.654615384615383,20.275384615384617,21.896153846153844,23.516923076923078,25.13769230769231,26.75846153846154,28.37923076923077,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":549.2,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":322.8,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":254.4,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":205.2,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":166.2,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":355.2,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":120,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":42.8,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.4,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.4,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >